The Effectiveness of Smoking Cessation in Prediabetic Smokers

Condition(s) studied

Investigational drug(s) / intervention(s)

Varenicline for tobacco smoking cessation: The 16-week varenicline course conforms to real-practice government regulations in Taiwan.

Individualized counseling about both smoking cessation and weight control techniques: The FIT2 program also offers behavior coaching in diet and physical activity to restrict post-cessation weight gain, which is not covered in conventional smoking cessation services.

Study summary

Existing literature investigating the impact of smoking cessation on new-onset diabetes mellitus (DM) risk is conflicting.

Combing the need for smoking cessation and body weight self-management to prevent the progression of prediabetes stage into DM, with the public implementation of the second-generation cessation program, we aimed to study the effectiveness of the Fight Tobacco and Stay Fit (FIT2) program aiming at promoting smoking cessation and restricting post-cessation weight gain (PCWG) together in prediabetic smokers regarding long-term glycemic and DM-related health outcomes.

Eligibility

Primary outcome measure(s)

• Number of Participants With New-onset Type 2 Diabetes Mellitus (DM) — Up to 5 years
  The primary outcome is type 2 DM, defined as having repeatedly at least one of the following criteria: 1) plasma glucose ≥126 mg/dL (7.0 mmol/L) in the fasting state; 2) plasma glucose ≥200 mg/dL (11.1 mmol/L) randomly with hyperglycemic symptoms or two hours after a 75-g oral glucose load; 3) A1C ≥6.5%;20 or under medications for physician-diagnosed type 2 DM.

Trial sites (1)

More National Taiwan University Hospital trials in Taiwan

Other trials for the same condition